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Experience with anidulafungin against Candida krusei is limited. Immunosuppressed mice were injected with
1.3  107 to 1.5  107 CFU of C. krusei. Animals were treated with saline, 40 mg/kg fluconazole, 1 mg/kg
amphotericin B, or 10 and 20 mg/kg anidulafungin for 5 days. Anidulafungin improved survival and signifi-
cantly reduced the number of CFU/g in kidneys and serum -glucan levels.
Non-albicans Candida species are increasing in incidence as
causes of invasive candidiasis in the United States and world-
wide (11). This is particularly important as Candida krusei has
intrinsic resistance to azoles, and there are reports of reduced
susceptibility to amphotericin B (AMB) (9, 16, 17). Recent
research has shown that even minor delays in appropriate
antifungal therapy are associated with increased morbidity and
mortality and that it is difficult to predict non-albicans Candida
species infection reliably (2, 3).
Echinocandins are novel antifungals that have activity in
vitro activity against C. krusei and other non-albicans Candida
species (19, 21). Proof in an animal model that C. krusei can be
treated with anidulafungin (AFG) would be a valuable contri-
bution to the understanding of the drug, especially since clin-
ical trials have limited numbers of patients with infection by
these species. Our objective was to measure the efficacy of
AFG in terms of survival and organism burden as measured by
quantitative tissue cultures and serum (1,3)--D-glucan (BG)
levels in a murine model of C. krusei infection. BG levels are
emerging as possible surrogate marker to evaluate the re-
sponse to treatment of fungal infections (12).
(This study was presented as abstract M-1840 at the 47th
Interscience Conference on Antimicrobial Agents and Chemo-
therapy, Chicago, IL, 2007 [14].)
Animals. Male CF-1 mice (Harlan Sprague-Dawley) weigh-
ing 20 to 30 g were used in this study. This study was reviewed
and approved by the University of Texas Health Science Cen-
ter Animal Welfare Committee.
Isolate and inoculum. C. krusei strain LMR 39-14, a blood-
stream isolate from a clinical isolate collection, was used for all
experiments. The isolate species was confirmed by the API 32
method (Biomerieux), and antifungal susceptibility testing was
carried out by the CLSI M27-A3 microdilution method (1).
The MICs for fluconazole (FLU), AMB, and AFG were 64,
1.0, and 0.06 g/ml, respectively. Animals were inoculated by
intravenous tail injection with 1.3  107 to 1.5  107 CFU per
animal. Inocula were confirmed by serial plating after each
experiment.
Immunosuppression. Animals were immunosuppressed by a
single dose of 200 mg/kg of body weight fluorouracil (5-FU)
intraperitoneally (i.p.) 3 days prior to inoculation and a single
dose of 4 mg/kg of body weight dexamethasone subcutaneously
on the day of inoculation.
Experimental interventions. Twenty-five animals per group
were assigned to the following treatment regimens: (i) i.p.
normal saline every 24 h (q24h) (placebo) for 5 days, (ii) 10
mg/kg i.p. AFG q24h for 5 days, (iii) 20 mg/kg i.p. AFG q24h
for 5 days, (iv) 40 mg/kg i.p. FLU q24h for 5 days, and (v) 1
mg/kg i.p. AMB q24h for 5 days. AFG doses were based on
previous pharmacodynamic studies (4, 20). The experiment
was run in duplicate.
Evaluations. Fifteen animals from each group were ob-
served for survival. Five animals from each group were sacri-
ficed on day 5 postinoculation and five animals on day 10
postinoculation to harvest the kidneys and blood. Quantitative
tissue cultures were performed by homogenization of both
kidneys, serial dilutions, and plating on Sabouraud dextrose
agar. Plates were incubated for 48 h, and the numbers of CFU
per gram of tissue were recorded and calculated. The level of
BG in serum was measured using the Fungitell kit following
the manufacturer’s instructions (Fungitell package insert,
2007; Associates of Cape Cod, Falmouth, MA). The detection
thresholds were 40 CFU/g of tissue for quantitative cultures
and 31 pg/ml for BG (according to the Fungitell package in-
sert).
Statistical analysis. As results were similar between the du-
plicate runs, data were pooled for the final analysis. Survival
curves were estimated using the Kaplan-Meier product limit
method and compared using the log-rank test. Log-trans-
formed CFU counts and BG levels were compared by analysis
of variance and the Kruskal-Wallis method, respectively. Find-
ings were considered statistically significant if P was 0.05.
As shown in Fig. 1, survival was statistically improved for
both AFG groups compared to the saline, FLU, or AMB
groups. There were no significant differences among the two
AFG doses, and likewise there were no significant differences
* Corresponding author. Mailing address: Division of Infectious
Diseases, University of Texas Medical School at Houston, 6431 Fan-
nin, MSB 2.112, Houston, TX 77030. Phone: (713) 500-6733. Fax:
(713) 500-5495. E-mail: Luis.Ostrosky-Zeichner@uth.tmc.edu.
 Published ahead of print on 12 January 2009.
1639
between FLU and saline. AMB significantly prolonged survival
compared to saline and FLU.
As shown in Table 1, both doses of AFG produced a statis-
tically significant 2-log reduction of kidney CFU/g compared
to saline and FLU on day 5 and an4-log reduction by day 10.
No statistically significant reductions were seen for FLU or
AMB compared to saline, and no differences were seen be-
tween the two doses of AFG either. BG levels significantly
decreased with both AFG doses compared to saline, FLU, and
AMB on days 5 and 10. There were no significant differences
between the two doses or between the levels found for each
dose on day 5 and day 10.
AFG showed antifungal activity in this murine model of C.
krusei infection, as evidenced by improved survival and re-
duced organism burden by quantitative tissue cultures and
serum BG.
AFG shows good in vitro activity against C. krusei. ARTEMIS,
a global surveillance program (17), reported a MIC90 of 0.06
g/ml for 121 isolates of this species. As stated in the intro-
duction, there are no reports of animal models exploring the
efficacy of this agent in disease caused by this particular spe-
cies. Clinical experience has anecdotally shown variable re-
sponse rates of C. krusei to AFG. In the first open-label expe-
rience with AFG and candidemia, Krause et al. (7) reported
five cases of disease caused by C. krusei infection, one of which
was considered a microbiological failure at the end of therapy.
The largest randomized trial of AFG for invasive candidiasis
systematically excluded patients with infection by C. krusei
since the comparator was FLU (18). Development of resis-
tance while under treatment appears to be rare. Marr et al.
FIG. 1. Kaplan-Meier plot of survival estimates for immunocompromised CF-1 mice infected with 1.3  107 to 1.5  107 CFU of C. krusei by
intravenous tail injection. Treatment group abbreviations (n  30): Saline, i.p. normal aline solution; Anidula 10 MKD, 10 mg/kg/day i.p. AFG;
Anidula 20 MKD, 20 mg/kg/day i.p. AFG; Flu 40 MKD, 40 mg/kg/day i.p. FLU; AMB 1 MKD, 1 mg/kg/day i.p. AMB. Both AFG doses statistically
improved survival (P  0.05) compared to placebo, AMB, or FLU. AMB statistically improved survival (P  0.05) compared to placebo and FLU.
TABLE 1. Tissue burden in kidneys and BG levels in serum
Treatment
groupa













Uninfected ND 52 	 30 ND 44 	 72
Saline 6.66 	 0.30 1,942 	 574 5.22 	 2.17 1,670 	 962
FLU 7.01 	 0.56 2,714 	 2,636 4.77 	 1.74 1,292 	 734
AMB 5.95 	 0.47 2,559 	 2,872 4.96 	 0.66 1,742 	 1,108
AFG10 4.06 	 0.38*†‡ 256 	 144*†‡ 0.96 	 1.54*†‡ 624 	 497*†‡
AFG20 3.97 	 0.34*†‡ 351 	 264*†‡ 1.59 	 1.68*†‡ 693 	 816*‡
a The treatment regimens were as follows: Saline, normal saline solution q24h
(placebo) for 5 days; FLU, 40 mg/kg i.p. FLU q24h for 5 days; AMB, 1 mg/kg i.p.
AMB q24h for 5 days; AFG10, 10 mg/kg i.p. AFG q24h for 5 days; and AFG20,
20 mg/kg i.p. q24h for 5 days.
b Log10-transformed CFU were compared by analysis of variance, and BG
levels were compared by the Kruskal-Wallis method. ND, not determined. , P
0.05 compared to saline; †, P  0.05 compared to FLU; ‡, P  0.05 compared to
saline.
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(5, 6) reported a C. krusei strain from a patient with leukemia
that displayed reduced susceptibility to echinocandin drugs:
the strain contained a heterozygous mutation of FKS1. Other
echinocandins have consistently shown good activity against
C. krusei in a limited number of patients in clinical trials (8, 10,
13, 15).
This study provides information regarding the in vivo activity
of AFG against C. krusei. AFG seemed effective in controlling
the infection in this murine model of disease, as evidenced by
improved survival and reduced organism burden compared to
placebo and other antifungals. Further clinical experience is
warranted.
This study was funded by an Independent Investigator Research
grant from Pfizer, Inc.
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